Page last updated: 2024-10-30

mechlorethamine and Cancer, Second Primary

mechlorethamine has been researched along with Cancer, Second Primary in 80 studies

nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.

Research Excerpts

ExcerptRelevanceReference
"In the last two decades, it has become evident that secondary leukemias after Hodgkin's disease (HD) are mainly caused by the treatment with alkylating agents, especially mechlorethamine."9.08Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group. ( Creutzig, U; Gadner, H; Harbott, J; Mann, G; Riepenhausen, M; Ritter, J; Schellong, G, 1997)
"Colorectal cancer surveillance should be considered for HL survivors who received Infradiaphragmatic radiotherapy and a high cumulative procarbazine dose."7.85Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors. ( Aleman, BM; de Boer, JP; De Bruin, ML; Janus, CP; Kremer, LC; Krol, AD; Louwman, MW; Schaapveld, M; van der Maazen, RW; van Eggermond, AM; van Leerdam, ME; van Leeuwen, FE; Visser, O; Zijlstra, JM, 2017)
"In the last two decades, it has become evident that secondary leukemias after Hodgkin's disease (HD) are mainly caused by the treatment with alkylating agents, especially mechlorethamine."5.08Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group. ( Creutzig, U; Gadner, H; Harbott, J; Mann, G; Riepenhausen, M; Ritter, J; Schellong, G, 1997)
" The additional use of mechlorethamine or oral psoralen plus UV-A, but not radiation, was significantly associated with the development of basal cell carcinoma and squamous cell carcinoma, but not malignant melanoma."4.79Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation. ( Braverman, IM; Feldman, AM; Kacinski, BM; Licata, AG; Wilson, LD, 1995)
"Colorectal cancer surveillance should be considered for HL survivors who received Infradiaphragmatic radiotherapy and a high cumulative procarbazine dose."3.85Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors. ( Aleman, BM; de Boer, JP; De Bruin, ML; Janus, CP; Kremer, LC; Krol, AD; Louwman, MW; Schaapveld, M; van der Maazen, RW; van Eggermond, AM; van Leerdam, ME; van Leeuwen, FE; Visser, O; Zijlstra, JM, 2017)
" We describe a 5-year-old boy with stage IV HD, successfully treated with MOPP (mechlorethamine, vincristine, procarbazine, and prednisone)/ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy followed by 35 Gy mantle radiotherapy who developed primary hyperparathyroidism because of benign PTA at the age of 20 years, and died of CS in thoracic vertebrae at the age of 22 years."3.76Parathyroid adenoma and chondrosarcoma after treatment of pediatric Hodgkin disease. ( Albayrak, M; Coskun, U; Gursel, T; Kaya, Z; Keskin, EY; Kocak, U; Uluoglu, O, 2010)
"The cumulative dose of mechlorethamine was the most important factor in determining leukemia risk."3.69Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. ( Chorus, AM; Hagenbeek, A; Noyon, R; Pinedo, HM; Somers, R; van den Belt-Dusebout, AW; van Kerkhoff, EH; van Leeuwen, FE, 1994)
"Between 1978 and 1988, 20 children with medulloblastoma (MB) of the brain were treated postoperatively with MOPP (nitrogen mustard, vincristine, prednisone, and procarbazine)."3.68Therapy-related myelodysplastic syndrome in children with medulloblastoma following MOPP chemotherapy. ( Hayani, A; Mahoney, DH; Taylor, LD, 1992)
"The causes of death were Hodgkin's lymphoma in 36 patients, second neoplasms in 12, cardiorespiratory diseases in 4, pulmonary diseases in 2, and unknown in 6."2.72MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors. ( Broglia, C; Cavanna, L; Chisesi, T; Corazza, GR; Corbella, F; Federico, M; Gobbi, PG; Iannitto, E; La Sala, A; Levis, A; Molica, S; Pavone, V; Sacchi, S; Valentino, F, 2006)
"In early-stage Hodgkin's lymphoma (HL), subtotal nodal irradiation (STNI) and combined chemotherapy/radiotherapy produce high disease control rates but also considerable late toxicity."2.72Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. ( Aleman, BM; Bosq, J; Carde, P; Dupouy, N; Eghbali, H; Girinsky, T; Hagenbeek, A; Henry-Amar, M; Kluin-Nelemans, JC; Krol, AD; Monconduit, M; Noordijk, EM; Pény, AM; Raemaekers, JM; Thomas, J; Tirelli, U; Verschueren, TA; Vovk, M, 2006)
"Two cases developed a second malignancy."2.68Treatment of childhood Hodgkin's disease without radiotherapy. ( Behrendt, H; van den Berg, H; Zsiros, J, 1997)
"80% or more of patients suffering from Hodgkin's lymphoma (HD) of limited stage are cured with modern treatment."2.39[Current therapy concepts in early and intermediate stages of Hodgkin diseases in adults]. ( Glanzmann, C; Stahel, R, 1995)
"We reviewed all reported cases of Burkitt's lymphoma and/or Burkitt's leukemia (BLL) occurring following therapy for Hodgkin's disease."2.39Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease. ( Cooper, DL; Levy, A; Salloum, E; Tallini, G, 1996)
"Routine thyroid cancer screening may benefit females treated at a young age and ≥10 years from HL treatment owing to their higher risk, which increases over time."1.40Thyroid malignancies in survivors of Hodgkin lymphoma. ( Chen, YH; Marcus, KJ; Michaelson, EM; Ng, AK; Silver, B; Stevenson, MA; Tishler, RB, 2014)
"To assess therapy-related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS) risk in patients treated for Hodgkin lymphoma (HL) on successive generations of Stanford clinical trials."1.39Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. ( Advani, RH; Balise, R; Greenberg, PL; Hoppe, RT; Horning, SJ; Koontz, MZ; Rosenberg, SA, 2013)
"Ductal invasive carcinoma and ductal carcinoma in situ represented, respectively, 51 cases (71%) and 14 cases (19%)."1.38Locoregional treatment for breast carcinoma after Hodgkin's lymphoma: the breast conservation option. ( Belin, L; Bollet, MA; Campana, F; Decaudin, D; Fourquet, A; Haberer, S; Kirova, YM; Le Scodan, R; Moisson, P; Pierga, JY; Reyal, F; Savignoni, A; Stevens, D, 2012)
"The behavior of Hodgkin's lymphoma (HL) is different in developing countries, perhaps due to differences in epidemiology and population access to health care."1.35Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study. ( Alves, AC; Baiocchi, OC; Oliveira, JS; Souza, EM; Zanichelli, MA, 2009)
"The risk of stomach cancer was 3."1.35Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. ( Aleman, BM; Besseling, G; de Bruin, ML; de Wit, R; Gietema, JA; Hauptmann, M; Kerst, JM; Noordijk, EM; Ribot, JG; van 't Veer, MB; van den Belt-Dusebout, AW; van Leeuwen, FE, 2009)
"The treatment strategies of Hodgkin's lymphoma (HL) are different according to clinical stage and risk factors, yet the optimal treatment strategy remains unclear."1.34[Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases]. ( Hu, DS; Hu, S; Song, QB; Tan, WY; Wei, L; Zeng, FY; Zhou, LQ, 2007)
"Actuarial risk of second malignancy for adolescents and adults was not different (P = ."1.33Hodgkin's lymphoma in adolescents. ( Connors, JM; Foltz, LM; Song, KW, 2006)
"We consider as second cancer all tumours other than HD observed in patients after treatment for HD."1.32[Second malignancies following Hodgkin's disease treatment in Tunisia. Retrospective study of 26 cases observed at the institute Salah-Azaïz]. ( Belhaj Ali, Z; Benna, F; Besbes, M; Bouaouina, N; Boussen, H; Gammoudi, A; Ghilen, L; Kochbati, L; Maalej, M; Rahal, K, 2003)
"Risk of lung cancer was borderline significantly greater in patients treated with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) chemotherapy than those who did not receive this treatment (relative risk [RR] = 1."1.31Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. ( Allerton, R; Barber, JA; Cunningham, D; Horwich, A; Linch, DC; Lister, TA; Rohatiner, AZ; Schoemaker, MJ; Swerdlow, AJ; Vaughan Hudson, G; Williams, MV, 2001)
"The relative risk of second cancers overall was 27."1.30Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital. ( Barber, JA; Cunningham, D; Horwich, A; Milan, S; Omar, RZ; Swerdlow, AJ, 1997)
"In this series, risk factors for second cancer were age >/=40 years (RR = 3."1.30Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. ( André, M; Attal, M; Bastion, Y; Blaise, D; Cahn, JY; Colombat, P; Fermé, C; Fleury, J; Gisselbrecht, C; Henry-Amar, M; Kuentz, M; Milpied, N; Nedellec, G; Pico, JL, 1998)
"Patients treated with radiotherapy for Hodgkin's disease have a considerable risk for a second cancer in long-term follow-up."1.30Second cancer among long-term survivors from Hodgkin's disease. ( Joensuu, H; Muhonen, T; Nyandoto, P, 1998)
"Risk of leukemia was 0."1.30The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-con ( Anselmo, AP; Baroni, CD; Bernasconi, C; Brusamolino, E; Klersy, C; Lazzarino, M; Lunghi, F; Mandelli, F; Maurizi-Enrici, R; Orlandi, E; Pagnucco, G; Santoro, M, 1998)
"Hodgkin's disease is curable in the majority of patients, although a proportion of patients are resistant to or relapse after initial therapy."1.30High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. ( Devereux, S; Goldstone, AH; Gregory, W; Hancock, B; Harrison, CN; Hoskin, P; Hudson, GV; Linch, DC; MacMillan, AK; Milligan, D; Newland, AC; Winfield, D, 1999)
"In patients with advanced Hodgkin's disease (HD), the alternation of MOPP with ABVD or hybrid MOPP/ABVD are associated with a high CR rate and a high probability of 5-year survival."1.29Hybrid MOPP/ABVD and radiotherapy in advanced Hodgkin's disease. ( Aversa, S; Bianco, A; Chiarion Sileni, V; Fiorentino, MV; Mazzarotto, R; Pappagallo, GL; Salvagno, L; Scarzello, G; Sorarù, M; Sotti, G, 1995)
"The risk of second cancer was analyzed (1) relative to the general population and (2) between risk subgroups using the Cox proportional hazards model."1.29Second primary cancers in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen? ( Bodis, S; Bosq, J; Cosset, JM; Dietrich, PY; Hayat, M; Henry-Amar, M, 1994)
"Two cases of malignant schwannoma are reported 13 and 15 years following combined modality treatment for Hodgkin's disease."1.29Malignant schwannoma following treatment for Hodgkin's disease. ( Bridges, LR; Cartwright, SC; Dodwell, DJ; Fisher, PM; Stone, J, 1994)
"A case of Hodgkin's disease with isolated cerebral relapse is reported here."1.29Meningioma-like cerebral relapse of Hodgkin's disease. ( Catarini, M; Discepoli, G; Leoni, P; Montillo, M; Rychlicki, F; Scarpelli, M, 1994)
"Two patients developed breast cancer 14 and 8 years after treatment of Hodgkin's disease."1.29Breast cancer developing after therapy for Hodgkin's disease. ( Cascinu, S; Catalano, G; Fedeli, A, 1993)
"The occurrence of HIV associated non-Hodgkin's lymphoma (NHL) is a well recognized event."1.29Hodgkin's disease and non-Hodgkin's lymphoma in an HIV positive patient. ( Brody, J; Goh, JC; Kaplan, MH; Koduru, P; Lichtman, SM; Susin, M, 1993)
"We report a 54-year-old patient with Hodgkin's disease who achieved a complete remission after combined modality treatment."1.29Factor VIII inhibitor prior to and during secondary acute nonlymphocytic leukemia in a patient with cured Hodgkin's disease. ( Bendandi, M; Cantagalli, F; Macchi, S; Mancino, A; Simoncelli, F; Stefanati, V; Tura, S; Visani, G; Zaccaria, A; Zinzani, PL, 1995)
"Thirteen patients have died of their second malignancy, including two of a third malignancy, while four have been followed for less than one year."1.29Second malignant neoplasms in patients with Hodgkin's disease. ( Atkinson, CH; Colls, BM; Fitzharris, BM; Robinson, BA, 1994)
"A second neoplasm was found in 6 patients (6%), of whom 4 developed a myelodysplastic syndrome (MDS) and 2 a solid tumour."1.28[Second neoplasms as a late complication of the treatment of Hodgkin's disease]. ( Alvarez, A; Colomé, JA; del Potro, E; Díaz Mediavilla, J; González, FA; Martínez, R; Morales, MD; Villegas, A, 1992)
"20 untreated Hodgkin's disease patients and 1 patient relapsing after radiotherapy (17 stage IIB-IV and 4 stage I-IIA) were given doxorubicin, bleomycin, etoposide and prednisone on a 21-day cycle."1.28ABEP as primary chemotherapy for Hodgkin's disease. ( Alberto, P; Mermillod, B; Zulian, GB, 1992)
"These risks of second cancers are important in choice of treatment and in follow up of patients, but they are small compared with the great improvements in survival which have been brought about by modern therapeutic methods for Hodgkin's disease."1.28Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. ( Bennett, MH; Douglas, AJ; Hudson, BV; Hudson, GV; MacLennan, KA; Swerdlow, AJ, 1992)

Research

Studies (80)

TimeframeStudies, this research(%)All Research%
pre-19907 (8.75)18.7374
1990's41 (51.25)18.2507
2000's21 (26.25)29.6817
2010's10 (12.50)24.3611
2020's1 (1.25)2.80

Authors

AuthorsStudies
Mou, E1
Advani, RH2
von Eyben, R1
Rosenberg, SA2
Hoppe, RT3
van Eggermond, AM1
Schaapveld, M1
Janus, CP1
de Boer, JP1
Krol, AD2
Zijlstra, JM1
van der Maazen, RW3
Kremer, LC1
van Leerdam, ME1
Louwman, MW1
Visser, O1
De Bruin, ML2
Aleman, BM5
van Leeuwen, FE3
Lyons, AB1
Mitchell, DA1
Moy, RL2
Lindahl, LM1
Fenger-Grøn, M1
Iversen, L1
Michaelson, EM1
Chen, YH1
Silver, B1
Tishler, RB1
Marcus, KJ1
Stevenson, MA1
Ng, AK1
Knobler, R1
Almagro-Casado, E1
Sánchez, A1
Cantos, B1
Salas, C1
Pérez-Callejo, D1
Provencio, M1
Conway, JL1
Connors, JM2
Tyldesley, S1
Savage, KJ1
Campbell, BA1
Zheng, YY1
Hamm, J1
Pickles, T1
Mullah-Ali, A1
Ramsay, JA1
Bourgeois, JM1
Hodson, I1
Macdonald, P1
Midia, M1
Portwine, C1
Souza, EM1
Baiocchi, OC1
Zanichelli, MA1
Alves, AC1
Oliveira, JS1
van den Belt-Dusebout, AW2
Besseling, G1
Hauptmann, M1
van 't Veer, MB2
de Wit, R1
Ribot, JG1
Noordijk, EM2
Kerst, JM1
Gietema, JA1
Keskin, EY1
Gursel, T1
Uluoglu, O1
Albayrak, M1
Kaya, Z1
Coskun, U1
Kocak, U1
Haberer, S1
Belin, L1
Le Scodan, R1
Kirova, YM1
Savignoni, A1
Stevens, D1
Moisson, P1
Decaudin, D1
Pierga, JY1
Reyal, F1
Campana, F1
Fourquet, A1
Bollet, MA1
Koontz, MZ1
Horning, SJ1
Balise, R1
Greenberg, PL1
Metayer, C1
Curtis, RE1
Vose, J1
Sobocinski, KA1
Horowitz, MM1
Bhatia, S1
Fay, JW1
Freytes, CO1
Goldstein, SC1
Herzig, RH1
Keating, A1
Miller, CB1
Nevill, TJ1
Pecora, AL1
Rizzo, JD1
Williams, SF1
Li, CY1
Travis, LB2
Weisdorf, DJ1
Raemaekers, JM3
Tirelli, U2
Bortolus, R2
Lybeert, ML2
Keuning, JJ1
Carde, P2
Girinsky, T3
Tomsic, R1
Vovk, M2
van Hoof, A1
Demeestere, G2
Lugtenburg, PJ1
Thomas, J2
Schroyens, W1
De Boeck, K1
Baars, JW1
Kluin-Nelemans, JC2
Carrie, C1
Aoudjhane, M1
Bron, D1
Eghbali, H2
Smit, WG1
Meerwaldt, JH1
Hagenbeek, A3
Pinna, A2
Henry-Amar, M5
Longo, DL2
KONDO, T2
TSUKUI, K2
LARIONOV, LF1
LITVINOVA, EV1
KHOLDIN, SA1
SATO, H2
KAWASHIMA, Y1
KANNO, K1
NEMETH, L1
LAPIS, K1
BIHARI, E1
JAKOUBKOVA, J1
PALECEK, L1
Kochbati, L1
Boussen, H1
Benna, F1
Belhaj Ali, Z1
Gammoudi, A1
Bouaouina, N1
Besbes, M1
Ghilen, L1
Rahal, K1
Maalej, M1
Vassilakopoulos, TP1
Angelopoulou, MK1
Siakantaris, MP1
Kontopidou, FN1
Dimopoulou, MN1
Kokoris, SI1
Kyrtsonis, MC1
Tsaftaridis, P1
Karkantaris, C1
Anargyrou, K1
Boutsis, DE1
Variamis, E1
Michalopoulos, T1
Boussiotis, VA1
Panayiotidis, P1
Papavassiliou, C1
Pangalis, GA1
Kneller, A1
Cohen, N1
Berkowicz, M1
Reichart, M1
Rosner, E1
Sokolovski, M1
Nagler, A1
Rechavi, G1
Amariglio, N1
Trakhtenbrot, L1
Bonadonna, G2
Viviani, S2
Bonfante, V2
Gianni, AM1
Valagussa, P2
DeLair, SM1
White, RW1
Kurzrock, EA1
Morbidini-Gaffney, S1
Alpert, TE1
Hatoum, GF1
Sagerman, RH1
Gobbi, PG1
Broglia, C1
Levis, A1
La Sala, A1
Valentino, F1
Chisesi, T1
Sacchi, S1
Corbella, F1
Cavanna, L1
Iannitto, E1
Pavone, V1
Molica, S1
Corazza, GR1
Federico, M1
Fermé, C2
Mounier, N1
Casasnovas, O1
Brice, P1
Divine, M1
Sonet, A1
Bouafia, F1
Bastard-Stamatoullas, A1
Bordessoule, D1
Voillat, L1
Reman, O1
Blanc, M1
Gisselbrecht, C2
Foltz, LM1
Song, KW1
Dupouy, N1
Monconduit, M1
Bosq, J2
Verschueren, TA1
Pény, AM1
Tomiŝiĉ, R1
Baaijens, MH1
Lugtenburg, P1
Lievens, Y1
de Jong, D1
Diehl, V1
Fuchs, M1
Tan, WY1
Hu, DS1
Zeng, FY1
Song, QB1
Hu, S1
Wei, L1
Zhou, LQ1
Glanzmann, C1
Stahel, R1
Brusamolino, E2
Lazzarino, M2
Orlandi, E2
Canevari, A1
Morra, E1
Castelli, G1
Alessandrino, EP1
Pagnucco, G2
Astori, C1
Livraghi, A1
Zanini, M1
Santoro, A1
Soncini, F1
Devizzi, L1
Villani, F1
Castellani, MR1
Negretti, E1
Zucali, R1
Salvagno, L1
Sorarù, M1
Sotti, G1
Aversa, S1
Chiarion Sileni, V1
Mazzarotto, R1
Scarzello, G1
Bianco, A1
Pappagallo, GL1
Fiorentino, MV1
Bendandi, M1
Zaccaria, A1
Zinzani, PL1
Visani, G2
Stefanati, V1
Cantagalli, F1
Mancino, A1
Macchi, S1
Simoncelli, F1
Tura, S2
Boice, JD1
Lichtman, SM1
Brody, J1
Kaplan, MH1
Susin, M1
Koduru, P1
Goh, JC1
Licata, AG1
Wilson, LD1
Braverman, IM1
Feldman, AM1
Kacinski, BM1
Rysenga, E1
Linden, MD1
Carey, JL1
Ross, CW1
Schnitzer, B1
Sawdyk, M1
Maeda, K1
Montillo, M1
Scarpelli, M1
Discepoli, G1
Catarini, M1
Rychlicki, F1
Leoni, P1
Robinson, BA1
Colls, BM1
Fitzharris, BM1
Atkinson, CH1
Dietrich, PY1
Cosset, JM1
Bodis, S1
Hayat, M1
Smoller, BR1
Marcus, R1
Fisher, PM1
Dodwell, DJ1
Bridges, LR1
Cartwright, SC1
Stone, J1
Chorus, AM1
Noyon, R1
van Kerkhoff, EH1
Pinedo, HM1
Somers, R1
Cascinu, S1
Fedeli, A1
Catalano, G1
Jenkin, D1
Greenberg, M1
Fitzgerald, A1
Salloum, E1
Tallini, G1
Levy, A1
Cooper, DL1
Swerdlow, AJ3
Barber, JA2
Horwich, A2
Cunningham, D2
Milan, S1
Omar, RZ1
Redei, I1
Mangan, KF1
Ming, PL1
Mullaney, MT1
Rao, PN1
Goldberg, SL1
Klumpp, TR1
van den Berg, H1
Zsiros, J1
Behrendt, H1
Schellong, G1
Riepenhausen, M1
Creutzig, U1
Ritter, J1
Harbott, J1
Mann, G1
Gadner, H1
Tsodikov, A1
Loeffler, M1
Yakovlev, A1
Crowley, JJ1
Nikko, A1
Varghese, A1
Kim, YH1
Lamb, PM1
Menaker, GM1
Andrieu, JM1
Colonna, P1
André, M1
Blaise, D1
Colombat, P1
Fleury, J1
Milpied, N1
Cahn, JY1
Pico, JL1
Bastion, Y1
Kuentz, M1
Nedellec, G1
Attal, M1
Arranz, R1
Gil-Fernández, JJ1
Muñoz, E1
Acevedo, A1
Sobrino, MP1
Fernández-Rañada, JM1
Nyandoto, P1
Muhonen, T1
Joensuu, H1
Anselmo, AP1
Klersy, C1
Santoro, M1
Lunghi, F1
Maurizi-Enrici, R1
Baroni, CD1
Mandelli, F1
Bernasconi, C1
Aisenberg, AC1
Lemoli, RM1
Leopardi, G1
Motta, MR1
Rizzi, S1
Testoni, N1
Curti, A1
Harrison, CN1
Gregory, W1
Hudson, GV2
Devereux, S1
Goldstone, AH1
Hancock, B1
Winfield, D1
MacMillan, AK1
Hoskin, P1
Newland, AC1
Milligan, D1
Linch, DC2
Schoemaker, MJ1
Allerton, R1
Lister, TA2
Rohatiner, AZ1
Vaughan Hudson, G1
Williams, MV1
Cellai, E1
Magrini, SM1
Masala, G1
Alterini, R1
Costantini, AS1
Rigacci, L1
Olmastroni, L1
Papi, MG1
Spediacci, MA1
Innocenti, F1
Bellesi, G1
Ferrini, PR1
Biti, G1
Morales, MD1
González, FA1
Villegas, A1
del Potro, E1
Díaz Mediavilla, J1
Martínez, R1
Alvarez, A1
Colomé, JA1
Avilés, A1
Díaz-Maqueo, JC1
Ayala, JR1
Cortés, HD1
García, EL1
Ganesan, TS1
Oza, A1
Perry, N1
D'Ardenne, J1
Arnott, S1
Stansfeld, AG1
Shand, WS1
Wrigley, PF1
Zulian, GB1
Mermillod, B1
Alberto, P1
Douglas, AJ1
Hudson, BV1
Bennett, MH1
MacLennan, KA1
Hayani, A1
Mahoney, DH1
Taylor, LD1
DeVita, VT1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase III Randomized Trial of Adjuvant Involved-Field Radiotherapy vs No Adjuvant Therapy Following Remission Induction With MOPP/ABV Hybrid Chemotherapy in Patients With Stage III/IV Hodgkin's Disease[NCT00002462]Phase 3615 participants (Actual)Interventional1989-09-30Active, not recruiting
Evaluation of Late Treatment Effects in Long-Term Survivors of Hodgkin's Disease Previously Treated at NIH: A Multi-Institutional Trial[NCT00924131]157 participants (Anticipated)Observational2009-04-17Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

8 reviews available for mechlorethamine and Cancer, Second Primary

ArticleYear
Paraspinal synovial sarcoma as an unusual postradiation complication in pediatric abdominal neuroblastoma.
    Journal of pediatric hematology/oncology, 2008, Volume: 30, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 18; Chromosomes, Human, X;

2008
Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2007, Volume: 37, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cyclophosphamid

2007
[Current therapy concepts in early and intermediate stages of Hodgkin diseases in adults].
    Praxis, 1995, Oct-10, Volume: 84, Issue:41

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined

1995
Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation.
    Archives of dermatology, 1995, Volume: 131, Issue:4

    Topics: Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Electrons; Female; Humans; Lymphoma, T

1995
Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease.
    Cancer investigation, 1996, Volume: 14, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Burkitt Lymphoma; Cyclophosphamide

1996
[Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
    Sangre, 1998, Volume: 43, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Combined

1998
Problems in Hodgkin's disease management.
    Blood, 1999, Feb-01, Volume: 93, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplant

1999
The use of combination chemotherapy in the treatment of early stage Hodgkin's disease.
    Important advances in oncology, 1992

    Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality

1992

Trials

10 trials available for mechlorethamine and Cancer, Second Primary

ArticleYear
Involved-field radiotherapy for advanced Hodgkin's lymphoma.
    The New England journal of medicine, 2003, Jun-12, Volume: 348, Issue:24

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit

2003
MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jan-15, Volume: 12, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit

2006
Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
    Blood, 2006, Jun-15, Volume: 107, Issue:12

    Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Com

2006
Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jul-01, Volume: 24, Issue:19

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit

2006
Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.
    International journal of radiation oncology, biology, physics, 2007, Jan-01, Volume: 67, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit

2007
Extended-field radiotherapy in favorable stage IA-IIA Hodgkin's disease (prognostic role of stage).
    International journal of radiation oncology, biology, physics, 1994, Nov-15, Volume: 30, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit

1994
Treatment of childhood Hodgkin's disease without radiotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8 Suppl 1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Combined Modality Ther

1997
Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:6

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Child

1997
Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Disease-Free Survival; Doxor

1998
The use of combination chemotherapy in the treatment of early stage Hodgkin's disease.
    Important advances in oncology, 1992

    Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality

1992

Other Studies

63 other studies available for mechlorethamine and Cancer, Second Primary

ArticleYear
Long-Term Outcomes of Patients With Early Stage Nonbulky Hodgkin Lymphoma Treated With Combined Modality Therapy in the Stanford V Trials (the G4 and G5 Studies).
    International journal of radiation oncology, biology, physics, 2021, 06-01, Volume: 110, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Cyclophospham

2021
Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors.
    British journal of cancer, 2017, Jul-25, Volume: 117, Issue:3

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Colon; Colo

2017
Topical chemotherapy for numerous superficial basal cell carcinomas years after isolated limb perfusion for melanoma.
    Cutis, 2019, Volume: 103, Issue:5

    Topics: Administration, Cutaneous; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents

2019
Secondary cancers, comorbidities and mortality associated with nitrogen mustard therapy in patients with mycosis fungoides: a 30-year population-based cohort study.
    The British journal of dermatology, 2014, Volume: 170, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cause of Death; Cohor

2014
Thyroid malignancies in survivors of Hodgkin lymphoma.
    International journal of radiation oncology, biology, physics, 2014, Mar-01, Volume: 88, Issue:3

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc

2014
Nitrogen mustard revisited.
    The British journal of dermatology, 2014, Volume: 170, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Female; Humans; Male; Mechlorethamine; Mycosis Fungoides; Neoplas

2014
Lung cancer and other second neoplasms after treatment of Hodgkin lymphoma.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2016, Volume: 18, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Dox

2016
Secondary Breast Cancer Risk by Radiation Volume in Women With Hodgkin Lymphoma.
    International journal of radiation oncology, biology, physics, 2017, 01-01, Volume: 97, Issue:1

    Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy

2017
Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
    Annals of hematology, 2009, Volume: 88, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brazil; Dacarbaz

2009
Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy.
    International journal of radiation oncology, biology, physics, 2009, Dec-01, Volume: 75, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cohort Studies; Combine

2009
Parathyroid adenoma and chondrosarcoma after treatment of pediatric Hodgkin disease.
    Journal of pediatric hematology/oncology, 2010, Volume: 32, Issue:7

    Topics: Adenoma; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child, Preschool; Chondrosarcoma

2010
Locoregional treatment for breast carcinoma after Hodgkin's lymphoma: the breast conservation option.
    International journal of radiation oncology, biology, physics, 2012, Feb-01, Volume: 82, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neoplasms

2012
Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Feb-10, Volume: 31, Issue:5

    Topics: Academic Medical Centers; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Californ

2013
Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study.
    Blood, 2003, Mar-01, Volume: 101, Issue:5

    Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemoth

2003
Radiation therapy in the treatment of Hodgkin's disease--do you see what I see?
    Journal of the National Cancer Institute, 2003, Jul-02, Volume: 95, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neoplasms; Chemotherapy, Adjuvant;

2003
On production of metastases from rat tumor by nitrogen-mustard-N-oxide, x-ray, and cortisone.
    Gan, 1956, Volume: 47, Issue:3-4

    Topics: Animals; Cortisone; Mechlorethamine; Mustard Plant; Neoplasms; Neoplasms, Experimental; Neoplasms, S

1956
[Chemotherapy of mammary gland cancer metastases].
    Voprosy onkologii, 1956, Volume: 2, Issue:6

    Topics: Breast; Breast Neoplasms; Humans; Mammary Glands, Human; Mechlorethamine; Neoplasms, Second Primary;

1956
Experimental studies on the effects of nitromin upon tumor growth, with special respect to inhibition of metastasis production.
    Gan, 1957, Volume: 48, Issue:4

    Topics: Animals; Mechlorethamine; Neoplasms; Neoplasms, Experimental; Neoplasms, Second Primary; Nitrogen Mu

1957
[Effects of radiotherapy and chemotherapy on metastases of Guerin rat carcinoma].
    Strahlentherapie, 1959, Volume: 108, Issue:2

    Topics: Animals; Mannitol; Mechlorethamine; Neoplasms, Experimental; Neoplasms, Second Primary; Nitrogen Mus

1959
[On the treatment of metastases of malignant epithelial tumors with chloralkylamine preparations].
    Neoplasma, 1959, Volume: 6

    Topics: Carcinoma; Mechlorethamine; Neoplasms, Second Primary; Nitrogen Mustard Compounds

1959
Effects of nitrogen mustard N-oxide, x-rays, and cortisone on Yoshida sarcoma metastasis development.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1959, Volume: 102

    Topics: Animals; Cortisone; Mechlorethamine; Neoplasms; Neoplasms, Second Primary; Nitrogen Mustard Compound

1959
Experimental studies on the effects of nitromin (nitrogen mustard N-oxide) upon tumor growth, with special respect to inhibition of metastasis formation.
    Acta - Unio Internationalis Contra Cancrum, 1959, Volume: 15(Suppl 1)

    Topics: Animals; Mechlorethamine; Neoplasms; Neoplasms, Experimental; Neoplasms, Second Primary; Nitrogen Mu

1959
[Second malignancies following Hodgkin's disease treatment in Tunisia. Retrospective study of 26 cases observed at the institute Salah-Azaïz].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2003, Volume: 7, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Dacarbazine; Do

2003
Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
    International journal of radiation oncology, biology, physics, 2004, Jul-01, Volume: 59, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemothera

2004
Acquisition of a Ph chromosome with minor BCR/ABL fusion in treatment-related myelodysplastic syndrome with chromosome 7 abnormalities in a patient treated for Hodgkin disease.
    Cancer genetics and cytogenetics, 2005, Volume: 159, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chromosome Aberrations; Chromosome

2005
Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute.
    European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cause of Death; Dacarbazine; Disea

2005
Secondary transitional cell carcinoma and nitrogen mustard treatment.
    Urology, 2005, Volume: 65, Issue:6

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Carcinoma, Transitional Cell; Hodgkin Disease; Humans

2005
Benign pleural schwannoma secondary to radiotherapy for Hodgkin disease.
    American journal of clinical oncology, 2005, Volume: 28, Issue:6

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Basal Cell; Combin

2005
Hodgkin's lymphoma in adolescents.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-01, Volume: 24, Issue:16

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; British Columbia; Chem

2006
[Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases].
    Ai zheng = Aizheng = Chinese journal of cancer, 2007, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Co

2007
Early-stage Hodgkin's disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5 Suppl 2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cause of Death; Combin

1994
Hybrid MOPP/ABVD and radiotherapy in advanced Hodgkin's disease.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:2

    Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomyc

1995
Factor VIII inhibitor prior to and during secondary acute nonlymphocytic leukemia in a patient with cured Hodgkin's disease.
    Leukemia & lymphoma, 1995, Volume: 16, Issue:5-6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Blood Transfusion; Combined Modality

1995
Body wars: effect of friendly fire (cancer therapy)
    Journal of the National Cancer Institute, 1995, May-17, Volume: 87, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Hodgkin

1995
Hodgkin's disease and non-Hodgkin's lymphoma in an HIV positive patient.
    Leukemia & lymphoma, 1993, Volume: 9, Issue:4-5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cyclophosphamide; Dexametha

1993
Peripheral T-cell non-Hodgkin's lymphoma following treatment of nodular lymphocyte predominance Hodgkin's disease.
    Archives of pathology & laboratory medicine, 1995, Volume: 119, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Hodgkin Disease; Humans; Lymphocytes; Lymphoma, B-Ce

1995
Meningioma-like cerebral relapse of Hodgkin's disease.
    Leukemia & lymphoma, 1994, Volume: 14, Issue:1-2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fatal Outcome; Female; Ho

1994
Second malignant neoplasms in patients with Hodgkin's disease.
    Australian and New Zealand journal of medicine, 1994, Volume: 24, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Combined Moda

1994
Second primary cancers in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen?
    Blood, 1994, Aug-15, Volume: 84, Issue:4

    Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modal

1994
Risk of secondary cutaneous malignancies in patients with long-standing mycosis fungoides.
    Journal of the American Academy of Dermatology, 1994, Volume: 30, Issue:2 Pt 1

    Topics: Carcinoma in Situ; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Follow-Up Studies; H

1994
Malignant schwannoma following treatment for Hodgkin's disease.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 1994, Volume: 6, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Female

1994
Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:5

    Topics: Adult; Aged; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Case-Co

1994
Breast cancer developing after therapy for Hodgkin's disease.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 1993, Volume: 5, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intr

1993
Second malignant tumours in childhood Hodgkin's disease.
    Medical and pediatric oncology, 1996, Volume: 26, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Protocols; Cohort

1996
Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital.
    British journal of cancer, 1997, Volume: 75, Issue:1

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc

1997
Detection of a dormant 20q- leukemia clone in bone marrow cultures with hematopoietic growth factors: implications for secondary leukemia post-transplant.
    Bone marrow transplantation, 1997, Volume: 19, Issue:5

    Topics: Acute Disease; Adult; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; An

1997
A cure model with time-changing risk factor: an application to the analysis of secondary leukaemia. A report from the International Database on Hodgkin's Disease.
    Statistics in medicine, 1998, Jan-15, Volume: 17, Issue:1

    Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Fr

1998
Mycosis fungoides in young patients: clinical characteristics and outcome.
    Journal of the American Academy of Dermatology, 1998, Volume: 38, Issue:5 Pt 1

    Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents, Alkylating; Case-Control Studies; Cause of De

1998
Multiple basal cell carcinomas of the limb after adjuvant treatment of melanoma with isolated limb perfusion.
    Journal of the American Academy of Dermatology, 1998, Volume: 38, Issue:5 Pt 1

    Topics: Antineoplastic Agents, Alkylating; Carcinoma, Basal Cell; Chemotherapy, Adjuvant; Chemotherapy, Canc

1998
Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease.
    Blood, 1998, Sep-15, Volume: 92, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Female; Hematopoietic Stem

1998
Second cancer among long-term survivors from Hodgkin's disease.
    International journal of radiation oncology, biology, physics, 1998, Sep-01, Volume: 42, Issue:2

    Topics: Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleom

1998
Hodgkin's disease and the risk of acute leukemia in successfully treated patients.
    Haematologica, 1998, Volume: 83, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Dacarbazine; D

1998
The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-con
    Haematologica, 1998, Volume: 83, Issue:9

    Topics: Abdomen; Actuarial Analysis; Acute Disease; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over;

1998
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Bone marrow transplantation, 1999, Volume: 23, Issue:3

    Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Mod

1999
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    British journal of cancer, 1999, Volume: 81, Issue:3

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine;

1999
Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Mar-15, Volume: 19, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Female; Hodgkin D

2001
The risk of second malignant tumors and its consequences for the overall survival of Hodgkin's disease patients and for the choice of their treatment at presentation: analysis of a series of 1524 cases consecutively treated at the Florence University Hosp
    International journal of radiation oncology, biology, physics, 2001, Apr-01, Volume: 49, Issue:5

    Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; F

2001
[Second neoplasms as a late complication of the treatment of Hodgkin's disease].
    Sangre, 1992, Volume: 37, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom

1992
Hodgkin's disease and acute leukemia. Is it a true association?
    Archives of medical research, 1992,Spring, Volume: 23, Issue:1

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil

1992
Management of stage II Hodgkin's disease: 15 years experience at St. Bartholomew's Hospital.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1992, Volume: 3, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit

1992
ABEP as primary chemotherapy for Hodgkin's disease.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:10

    Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cytarabin

1992
Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation.
    BMJ (Clinical research ed.), 1992, May-02, Volume: 304, Issue:6835

    Topics: Adolescent; Adult; Alkylating Agents; Child; Chlorambucil; Cohort Studies; Female; Follow-Up Studies

1992
Therapy-related myelodysplastic syndrome in children with medulloblastoma following MOPP chemotherapy.
    Journal of neuro-oncology, 1992, Volume: 14, Issue:1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool

1992